Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarctionl - T-VENTURE study

Circulation Journal

Volumn 73, Issue 5, 2009, Pages 918-924

  Suzuki, Hiroshi ^a,e   Geshi, Eiichi ^a   Nanjyo, Shuji ^b   Nakano, Hajime ^b   Yamazaki, Jyunichi ^b   Sato, Naoki ^c   Tanaka, Keiji ^c   Takano, Teruo ^c   Yagi, Hidenori ^d   Shibata, Takahiro ^d   Mochizuki, Seibu ^d   Katagiri, Takashi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Myocardial infarction; Myocardial remodeling

Indexed keywords

ACETYLSALICYLIC ACID; ALACEPRIL; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; LISINOPRIL; NICORANDIL; NITRIC ACID DERIVATIVE; PERINDOPRIL; SPIRONOLACTONE; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN; WARFARIN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; DRY COUGH; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART VENTRICULOGRAPHY; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE VOLUME; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 65649109725     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0959     Document Type: Article

References (23)

1. Shiraishi J, Kohno Y, Sawada R, Arihara M, Hyogo M, Yagi T, et al and The AMI-Kyoto Multi-Center Risk Study Group. Effects of hospital volume of primary percutaneous coronary interventions on angiographic results and in-hospital outcomes for acute myocardial infarction. Circulation J 2007; 72: 1041-1046.
2. Tani S, Nagao K, Watanabe I, Kikushima K, Watanabe K, Anazawa T, et al. Increasingly well-preserved left ventricular function in hospital survivors with acute myocardial infarction: Effect of early and complete reperfusion strategy on left ventricular remodeling. Circ J 2007; 71: 180-185. (Pubitemid 46182689)
3. Pfeffer MA, Branwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172. (Pubitemid 20119612)
4. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al for the SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 1994; 89: 68-75. (Pubitemid 24026473)
5. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trails. Circulation 1998; 97: 2202-2212. (Pubitemid 28265381)
6. Bonarjee VV, Carstensen S, Caidahl K, Nilsen DW, Edner M, Berning J. Attenuation of left ventricular dilatation after acute myocardial infarction by early initiation of enalapril therapy. Am J Cardiol 1993; 72: 1004-1009. (Pubitemid 23319921)
7. Tang WH, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, et al. Neurohumoral and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70-78. (Pubitemid 34059863)
8. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II forming pathways in the human heart. Circ Res 1997; 80: 219-227. (Pubitemid 27056985)
9. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999; 33: 613-621. (Pubitemid 29091636)
10. Kohno T, Anzai T, Naito K, Sugano Y, Maekawa Y, Takahashi T, et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J 2008; 72: 1685-1692.
11. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomized trial. Lancet 2002; 360: 752-760.
12. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003; 349: 1893-1906.
13. Dodge HT, Sandler H, Ballew DW, Lord JD Jr. The use of biplane angiography for the measurement of left ventricular volume in man. Am Heart J 1960; 60: 762-776.
14. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HR, Wood J. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761-771. (Pubitemid 23279290)
15. de Gasparo M, Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regulatory Peptides 1995; 59: 303-311.
16. Hudson M, Humphries K, Tu JV, Behlouli H, Sheppard R, Pilote L. Angiotensin II receptor blockers for the treatment of heart failure: A class effect? Pharmacother 2007; 27: 526-534. (Pubitemid 46536233)
17. Ueshima K, Fukami K, Hiramori K, Hosoda S, Kishida H, Kato K, et al; Japanese Acute Myocardial Infarction Prospective study group. Is angiotensin-converting enzyme inhibitor useful in a Japanese population for secondary prevention after acute myocardial infarction? A final report of the Japanese Acute Myocardial Infarction Prospective (JAMP) study. Am Heart J 2004; 148: e8. (Pubitemid 39092794)
18. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: Patterns of left ventricular dilatation and long-term prognostic implications. Circulation 2002; 106: 2351-2357. (Pubitemid 35244737)
19. Araszkiewicz A, Grajek S, Lesiak M, Prech M, Pyda M, Janus M, et al. Effect of impaired myocardial reperfusion on left ventricular remodeling in patients with anterior wall acute myocardial infarction treated with primary coronary intervention. Am J Cardiol 2006; 98: 725-728. (Pubitemid 44301004)
20. Nagashima M, Itoh A, Otsuka M, Kasanuki H, Haze K. Reperfusion phenomenon is a strong predictor of left ventricular remodeling after acute myocardial infarction. Circ J 2005; 69: 884-889. (Pubitemid 41124253)
21. Jeremy RW, Hackworthy RA, Bautovich G, Hutton BF, Harris PJ. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction. J Am Coll Cardiol 1987; 9: 989-995. (Pubitemid 17065754)
22. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction: Potential mechanisms and early predictors. Circulation 1993; 87: 755-763. (Pubitemid 23070806)
23. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172. (Pubitemid 20119612)